arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Forte Biosciences, Inc.

FBRX
$76.96 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Forte Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -117.6% ↘
FCF / Share None
Trailing P/E —
Price / Book 16.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Aug 26, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$36.00K
↓ -99.8% —
Net Income Profit after all expenses
$-69.38M
↓ -95.5% —
Long-Term Debt Long-term obligations
$26.20M
↑ +622.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
7
Cash Quality →
50

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 44 quarters